CSA Medical ices $23m funding round

CSA Medical said yesterday that it put a $23 million debt-and-equity round on ice for the cryospray technology it’s developing. Boston-based CSA said Horizon Technology Finance led the round with a $15 million loan facility; existing shareholders ponied up $8 million in equity financing, the company said. The round’s first tranche included a $6 million loan from Horizon and another $5 million in equity financing from backers including SV Health Investors, Ascension Ventures and Intersouth Partners, CSA said. Proceeds are earmarked for expanding the commercial footprint into gastrointestinal indications for its TruFreeze cryospray and further clinical and regulatory work on its Rejuvenair lung treatment, according to a press release. “Thanks to the support of our existing investors and new partner Horizon, we will continue to expand the market for truFreeze to treat the full spectrum of esophageal diseases including cancer and we will continue to advance Rejuvenair to improve quality of life for COPD patients,” chairman Vincent Owens said in prepared remarks. “This growth capital comes at an exciting moment in CSA’s corporate evolution as the growing body of evidence and patient success stories underscore truFreeze’s critical role in treating a wide range of esophageal disorders,” added TruFreeze president Wendelin Maners. “We are committed to supporting clinical and commercial programs that will dramatically...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Wall Street Beat CSA Medical Inc. Source Type: news

Related Links:

ConclusionsUnlike [18F]FDG, [18F]BODIPY 1 showed prominent accumulation in BAT under both inactive and stimulated status. [18F]BODIPY 1 may serve as a valuable BAT PET agent to possibly assess BAT mitochondria density, thus BAT thermogenic capacity after further evaluation.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
ConclusionsHypoxia modulation may play a role in nal-IRI ’s mechanism of action. Nal-IRI demonstrated greater anti-tumor activity in the more aggressive and hypoxic tumor model. Furthermore, hypoxia imaging provided early prediction of treatment response.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
AbstractPurposeTo investigate and validate the potential role of a radiomics signature in predicting the side-specific probability of extracapsular extension (ECE) of prostate cancer (PCa).ProceduresThe preoperative magnetic resonance imaging data of 238 prostatic samples from 119 enrolled PCa patients were retrospectively assessed. The samples with were randomized in a two-to-one ratio into training (n = 74) and validation (n = 45) datasets. The radiomics features were derived from T2-weighted images (T2WIs). The optimal radiomics features were identified from the least absolute shrinkage and s...
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Publication date: Available online 25 May 2020Source: Life SciencesAuthor(s): Serena L'Abbate, Ilaria Russo, Claudia Kusmic
Source: Life Sciences - Category: Biology Source Type: research
Dear colleagues, please advise concerning this patient: 40 yo male, high PS, diagnosed a couple of years ago of colic cancer that was locally treated. Aug 2020: he was diagnosed of left parietal (at the level of the motor strip) solitary brain lesion. octobre 2020: he underwent a complete resection , followed by cavity SRS 18Gy /1 fr April 2020: refractory seizures MRI showed a relapsing left parietal cavity lesion, whose epicenter was next to the trolard vein. he was re-resected quasi... re-irradiation after single fraction cavity SRS? What dose?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums
Publication date: Available online 12 May 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Manny D. Bacolod, Aashiq H. Mirza, Jianmin Huang, Sarah F. Giardina, Philip B. Feinberg, Steven A. Soper, Francis Barany
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
To observe the surgical index at the different learning stages of thoraco-laparoscopic esophagectomy in the prone position for esophageal cancer and to investigate the learning curve of this surgical procedure.
Source: Journal of Cardiothoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Research article Source Type: research
We report that the loss of 4.1N correlated with progress in clinical stage, as well as poor survival in EOC patients. The loss of 4.1N induces EMT in adherent EOC cells and its expression inhibits anoikis resistance and EMT by directly binding and accelerating the degradation of 14-3-3 in suspension EOC cells. Furthermore, the loss of 4.1N could increase the rate of entosis, which aggravates cell death resistance in suspension EOC cells. Moreover, xenograft tumors in nude mice also show that the loss of 4.1N can aggravate peritoneal dissemination of EOC cells. Single-agent and combination therapy with a ROCK inhibitor and ...
Source: Protein and Cell - Category: Cytology Tags: Protein Cell Source Type: research
CSA Medical today released early results from a feasibility study exploring the use of its RejuvenAir Metered Cryospray system in treating patients with chronic bronchitis, touting improvements in quality of life for patients treated with the system. Results from the trial were presented at the 2018 European Respiratory Society Congress in Paris, the Boston-based company said. “We are encouraged by these positive safety and feasibility results and we’re moving forward with plans to initiate a worldwide pivotal study of RejuvenAir in chronic bronchitis in 2019. We look forward to advancing this novel therap...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Respiratory CSA Medical Inc. Source Type: news
More News: Bronchitis | Cancer | Cancer & Oncology | Chronic Obstructive Pulmonary | Cryotherapy | Esophagus Cancer | Funding | Gastroenterology | Study